GSK Stock Recent News
GSK LATEST HEADLINES
Shore Capital is sticking with its upbeat view on GSK PLC (LSE:GSK, NYSE:GSK), calling the stock “disproportionately discounted” after first-quarter numbers surpassed expectations and guidance was held, despite headwinds from foreign exchange and political noise around drug pricing. The key beat came on earnings, with core EPS up 5% at constant exchange rates to 44.9p, a full 10% ahead of consensus.
The British pharmaceutical giant said that its first-quarter sales rose to 7.52 billion pounds from 7.36 billion pounds the year prior.
British drugmaker GSK said on Wednesday it was "well positioned" to respond to any potential financial impact from sector-specific tariffs if they were implemented and it had identified options within its supply chain and productivity initiatives to mitigate any hit.
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.
We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta to have driven first-quarter sales performance.
First-quarter results from GSK PLC (LSE:GSK, NYSE:GSK) will focus on commentary around the outlook, including interpretation of US policy changes under vaccine sceptic health secretary Robert Kennedy Jnr, including recent vaccine performance in the US and China. Weakness in the first quarter is anticipated in the US from GSK's key vaccine franchises, RSV vaccine Arexvy and shingles vaccine Shingrix.
Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities for the treatment of a type of blood cancer in adults who had received at least one other therapy previously.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.